Search Clinical Trials
Recruiting
Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion (External Link)
This is a phase I/II study of haploidentical HCT (HHCT) with ex vivo TCRαβ+ and CD19+ depletion using the CliniMACS device in patients with hematological malignancies and non-malignant disorders. HHCT …
Baylor Role:
Lead Sponsor
Recruiting
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection (External Link)
The hemolytic uremic syndrome (HUS) is the most serious complication of high-risk Shiga toxin-producing Escherichia coli (STEC) infection and the most common cause of acquired acute kidney injury in otherwise …
Baylor Role:
Collaborator
Recruiting
IV Iron Trial for Anemia Related to Uterine Bleeding in Female Patients Presenting to the Emergency Department (External Link)
Iron deficiency anemia (IDA) is the most common hematologic disorder in the United States and worldwide. Patients with moderate to severe anemia often present to the acute care setting for …
Baylor Role:
Lead Sponsor
Recruiting
Oxytocin for Hypermobile Ehlers-Danlos Syndrome (External Link)
This will be a single-site study to evaluate the effect of IV oxytocin on chronic pain in female adult patients with hypermobile EDS. Oxytocin secretion in the body is dynamic …
Baylor Role:
Lead Sponsor
Recruiting
Improving Comprehensive Care of Cancer Patients (External Link)
Design Overview. This is a randomized controlled trial of a consecutive sample of 300 medically underserved breast, GI, and hematological cancer patients with comorbidities recruited from Harris Health Ben Taub …
Baylor Role:
Lead Sponsor
Recruiting
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population (External Link)
Transitioning from busulfan, hydroxyurea, IFN-α to tyrosine kinase inhibitors (TKIs) has dramatically altered the natural history of CML. Patients with CML appropriately managed with TKIs are able to benefit from …
Baylor Role:
Lead Sponsor
Recruiting
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease (External Link)
This is a follow-up trial to NYMC 526 (NCT01461837) to assess the safety, efficacy and toxicity of administering Defibrotide prophylaxis for high-risk sickle cell or beta thalassemia patients undergoing a …
Baylor Role:
Collaborator
Recruiting
Investigation of the Genetics of Hematologic Diseases (External Link)
Participants will be individuals (proband) receiving therapy or expert consultation regarding a non-malignant hematologic disorder. We propose to use genomics, transcriptomics, proteomics and metabolomic analysis coupled with family linkage studies …
Baylor Role:
Collaborator
Recruiting
Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) (External Link)
To make donor derived multiTAA-specific T cells, the investigators will collect blood from the patient's stem cell donor, and mix the donor's T cells with small pieces of tumor proteins …
Baylor Role:
Lead Sponsor
Recruiting
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma (External Link)
Up to 390 mL (78 teaspoons) of blood will be collected from the patient on one to three occasions over a two month period. Under certain conditions related to the …
Baylor Role:
Lead Sponsor